Charles River Laboratories International Inc. (NYSE:CRL) shares fell to a low of $347.14 before closing at $354.78. Intraday shares traded counted 0.39 million, which was 35.88% higher than its 30-day average trading volume of 604.09K. CRL’s previous close was $345.91 while the outstanding shares total 49.98M. The firm has a beta of 1.14, a 12-month trailing P/E ratio of 48.16, and a growth ratio of 2.92. The stock’s Relative Strength Index (RSI) is 68.93, with weekly volatility at 1.42% and ATR at 8.59. The CRL stock’s 52-week price range has touched low of $165.76 and a $349.13 high. The stock traded higher over the last trading session, gaining 2.56% on 06/10/21.
Investors have identified the Diagnostics & Research company Charles River Laboratories International Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $17.56 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Charles River Laboratories International Inc. (CRL) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CRL, the company has in raw cash 465.41 million on their books with 2.93 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.42 billion total, with 803.38 million as their total liabilities.
CRL were able to record 142.2 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by 237.91 million. In cash movements, the company had a total of 170.23 million as operating cash flow.
Potential earnings growth for Charles River Laboratories International Inc. (CRL)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, Charles River Laboratories International Inc. recorded a total of 824.57 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 14.25% coming in sequential stages and their sales for the 08/11/2021 quarter increasing by 4.07%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 516.29 million trying to sell their products during the last quarter, with the result yielding a gross income of 308.28 million. This allows shareholders to hold on to 49.98M with the recently reported earning now reading 1.28 cents per share. This is a figure that compared to analyst’s prediction for their 08/11/2021 (2.53 cents a share).
Having a look at the company’s valuation, the company is expected to record 11.32 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CRL sounds very interesting.
Is the stock of CRL attractive?
In related news, CSVP&Chief Accounting Officer, Knell Michael Gunnar sold 1,527 shares of the company’s stock in a transaction that recorded on Jun 04. The sale was performed at an average price of 335.24, for a total value of 511,906. As the sale deal closes, the CSVP&Chief Accounting Officer, Knell Michael Gunnar now sold 800 shares of the company’s stock, valued at 263,809. Also, Chairman, President and CEO, FOSTER JAMES C sold 9,577 shares of the company’s stock in a deal that was recorded on Jun 01. The shares were price at an average price of 332.23 per share, with a total market value of 3,181,749. Following this completion of acquisition, the Director, MASSARO GEORGE now holds 371 shares of the company’s stock, valued at 118,743. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.
13 out of 18 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Charles River Laboratories International Inc.. 1 analysts has assigned a Sell rating on the CRL stock. The 12-month mean consensus price target for the company’s shares has been set at $374.69.